Crypto derivatives should be banks’ ‘gateway drug’ to spot: B2C2

- By Joe Parsons
- @Joe_Parsons416
- 09 Jun 2022

Cash-settled crypto derivatives should not be the end goal for banks, according to one of the founders of crypto market-maker B2C2; rather they should be a “gateway drug” to trade the physical product, for which liquidity conditions have improved significantly.

Banks including Goldman Sachs and Nomura have been among the traditional finance world’s first movers in trading bitcoin futures and non-deliverable forwards, while several other futures commission merchants (FCMs) have offered clearing

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@fx-markets.com or view our subscription options here: https://subscriptions.fx-markets.com

You are currently unable to print this content. Please contact info@fx-markets.com to find out more.

You are currently unable to copy this content. Please contact info@fx-markets.com to find out more.

As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.

If you would like to purchase additional rights please email info@fx-markets.com

You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.

If you would like to purchase additional rights please email info@fx-markets.com